Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. Show more

Location: 1111 Lincoln Road, Miami Beach, FL, 33139, United States | Website: https://www.pasithea.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

6.355M

52 Wk Range

$0.65 - $7.50

Previous Close

$0.85

Open

$0.81

Volume

159,256

Day Range

$0.77 - $0.83

Enterprise Value

-5.621M

Cash

7.217M

Avg Qtr Burn

-3.122M

Insider Ownership

3.26%

Institutional Own.

10.95%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.